Brian R Landmann

US Patent:

6555133, Apr 29, 2003

Filed:

Apr 2, 2001

Appl. No.:

09/824071

Inventors:

John D. Buehler - Ambler PA
Brian R. Landmann - Hoboken NJ

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 920

US Classification:

424451, 424452, 424464, 424465, 5147723, 514778, 514781, 514885

Abstract:

The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.

US Patent:

62386956, May 29, 2001

Filed:

Apr 6, 1999

Appl. No.:

9/286902

Inventors:

John D. Buehler - Ambler PA
Brian R. Landmann - Hoboken NJ

Assignee:

DuPont Pharmaceuticals Company - Wilmington DE

International Classification:

A61K 920
A61K 948

US Classification:

424451

Abstract:

The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.